OncoMatch/Clinical Trials/NCT07779109
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)
Is NCT07779109 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for sbrt.
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT/VMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage INTERMEDIATE-HIGH RISK, HIGH RISK (other)
categorized by Intermediate-high risk and high risk primary endometrial cancer based on recent ESGO/ESTRO/ESMO Guidelines (2025)
Demographics
Prior therapy
Cannot have received: pelvic or abdominal radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07779109 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic or abdominal radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage INTERMEDIATE-HIGH RISK or HIGH RISK is required.
Is there an age limit?
Yes. Patients must be 110 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages